Variable platelet response to aspirin in patients with ischemic stroke

Cerebrovascular Diseases

Volumn 24, Issue 1, 2007, Pages 43-50

  Hohlfeld, Thomas ^a,b   Weber, Artur Aron ^a   Junghans, Ulrich ^a   Schumacher, Marc ^a   Boucher, Marc ^a   Schrör, Karsten ^a   Siebler, Mario ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

Author keywords

Aggregation; Aspirin; Platelets; Stroke; Thromboxane

Indexed keywords

ACETYLSALICYLIC ACID; ARACHIDONIC ACID; COLLAGEN; THROMBOXANE;

ADULT; AGED; ARTICLE; CEREBROVASCULAR ACCIDENT; CLINICAL ARTICLE; CLINICAL TRIAL; COLLAGEN SYNTHESIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG EFFECT; DRUG MECHANISM; FEMALE; HUMAN; MALE; PATIENT COMPLIANCE; PRIORITY JOURNAL; STROKE; THROMBOCYTE; THROMBOCYTE AGGREGATION;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; ARACHIDONIC ACID; ASPIRIN; BIOLOGICAL AVAILABILITY; BLOOD PLATELETS; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; COLLAGEN; CYCLOOXYGENASE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE; FEMALE; HUMANS; MALE; MIDDLE AGED; PATIENT COMPLIANCE; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; THROMBOXANE B2; TREATMENT OUTCOME;

EID: 34347404722     PISSN: 10159770     EISSN: None     Source Type: Journal    
DOI: 10.1159/000103115     Document Type: Article

References (39)

1. Yip HK, Liou CW, Chang HW, Lan MY, Liu JS, Chen MC: Link between platelet activity and outcomes after an ischemic stroke. Cerebrovasc Dis 2005;20:120-128.
2. Antithrombotic Trialist's Collaboration: Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Br Med J 2002;324:71-86.
3. Junghans U, Siebler M: Cerebral microembolism is blocked by tirofiban, a selective nonpeptide platelet glycoprotein IIb/IIIa receptor antagonist. Circulation 2003;107:2717-2721.
4. Markus HS, Droste DW, Kaps M, Larrue V, Lees KR, Siebler M, Ringelstein EB: Dual antiplatelet therapy with clopidogrel and aspirin in symptomatic carotid stenosis evaluated using Doppler embolic signal detection: the Clopidogrel and Aspirin for Reduction of Emboli in Symptomatic Carotid Stenosis (CARESS) trial. Circulation 2005;111:2233-2240.
5. Forbes CD: Secondary stroke prevention with low-dose aspirin, sustained release dipyridamole alone and in combination. ESPS Investigators. European Stroke Prevention Study. Thromb Res 1998;92:S1-S6.
6. Diener HC, Bogousslavsky J, Brass LM, Cimminiello C, Csiba L, Kaste M, Leys D, Matias-Guiu J, Rupprecht HJ: Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet 2004;364:331-337.
7. Helgason CM, Bolin KM, Hoff JA, Winkler SR, Mangat A, Tortorice KL, Brace LD: Development of aspirin resistance in persons with previous ischemic stroke. Stroke 1994;25:2331-2336.
8. Alberts MJ, Bergman DL, Molner E, Jovanovic BD, Ushiwata I, Teruya J: Antiplatelet effect of aspirin in patients with cerebrovascular disease. Stroke 2004;35:175-178.
9. Pongracz E: Measurement of platelet aggregation during antiplatelet therapy in ischemic stroke. Clin Hemorheol Microcirc 2004;30:237-242.
10. McCabe DJ, Harrison P, Mackie IJ, Sidhu PS, Lawrie AS, Purdy G, Machin SJ, Brown MM: Assessment of the antiplatelet effects of low to medium dose aspirin in the early and late phases after ischaemic stroke and TIA. Platelets 2005;16:269-280.
11. Sztriha LK, Sas K, Vecsei L: Aspirin resistance in stroke: 2004. J Neurol Sci 2005;229-230:163-169.
12. Berrouschot J, Schwetlick B, Twickel G, Fischer C, Uhlemann H, Siegemund T, Siegemund A, Roessler A: Aspirin resistance in secondary stroke prevention. Acta Neurol Scand 2006;113:31-35.
13. Uchiyama S, Nakamura T, Yamazaki M, Kimura Y, Iwata M: New modalities and aspects of antiplatelet therapy for stroke prevention. Cerebrovasc Dis 2006;21(suppl 1):7-16.
14. Hankey GJ, Eikelboom JW: Aspirin resistance. Lancet 2006;367:606-617.
15. Schrör K, Weber AA, Hohlfeld T: Aspirin 'resistance'. Blood Cells Mol Dis 2006;36:171-176.
16. Hayward CP, Harrison P, Cattaneo M, Ortel TL, Rao AK: Platelet function analyzer (PFA)-100 closure time in the evaluation of platelet disorders and platelet function. J Thromb Haemost 2006;4:312-319.
17. Weber A-A, Przytulski B, Schanz A, Hohlfeld T, Schrör K: Towards a definition of aspirin resistance: a typological approach. Platelets 2002;13:37-40.
18. 2 metabolism and results in an altered susceptibility to aspirin effects. Platelets 2000;11:177-182.
19. 2+ concentrations. Thromb Res 1994;75:233-242.
20. Schrör K, Seidel H: Blood-vessel wall arachidonate metabolism and its pharmacological modification in a new in vitro assay system. Naunyn-Schmiedeberg's Arch Pharmacol 1988;337:177-182.
21. 2 for their receptor are similar in washed human platelets. Biochem Biophys Res Commun 1988;157:733-739.
22. Weber AA, Liesener S, Hohlfeld T, Schrör K: 40 mg of aspirin are not sufficient to inhibit platelet function under conditions of limited compliance. Thromb Res 2000;97:365-367.
23. Hamann GF, Weimar C, Glahn J, Busse O, Diener HC: Adherence to secondary stroke prevention strategies - Results from the German Stroke Data Bank. Cerebrovasc Dis 2003;15:282-288.
24. Lago A, Tembl JI, Pareja A, Ponz A, Ferrer JM, Valles J, Santos MT: Adherence to aspirin in secondary prevention of ischemic stroke. Cerebrovasc Dis 2006;21:353-356.
25. Crowe B, Abbas S, Meany B, de Haan J, Cahill MR: Detection of aspirin resistance by PFA-100: prevalence and aspirin compliance in patients with chronic stable angina. Semin Thromb Hemost 2005;31:420-425.
26. Benedek IH, Joshi AS, Pieniaszek HJ, King SYP, Kornhauser DM: Variability in the pharmacokinetics and pharmacodynamics of low dose aspirin in healthy male volunteers. J Clin Pharmacol 1995;35:1181-1186.
27. Catella-Lawson F, Reilly MP, Kapoor SC, Cucchiara AJ, DeMarco S, Tournier B, Vyas SN, FitzGerald GA: Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 2001;345:1809-1817.
28. Capone ML, Sciulli MG, Tacconelli S, Grana M, Ricciotti E, Renda G, Di Gregorio P, Merciaro G, Patrignani P: Pharmacodynamic interaction of naproxen with low-dose aspirin in healthy subjects. J Am Coll Cardiol 2005;45:1295-1301.
29. Weber AA, Zimmermann K, Meyer-Kirchrath J, Schrör K: Cyclooxygenase-2 in human platelets as a possible factor in aspirin resistance. Lancet 1999;353:900.
30. Rocca B, Secchiero P, Ciabattoni G, Ranelletti FO, Catani L, Guidotti L, Melloni E, Maggiano N, Zauli G, Patrono C: Cyclooxygenase-2 expression is induced during human megakaryopoiesis and characterizes newly formed platelets. Proc Natl Acad Sci USA 2002;99:7634-7639.
31. Warner TD, Mitchell JA: Cyclooxygenases: new forms, new inhibitors, and lessons from the clinic. FASEB J 2004;18:790-804.
32. Zimmermann N, Wenk A, Kim U, Kienzle P, Weber AA, Gams E, Schrör K, Hohlfeld T: Functional and biochemical evaluation of platelet aspirin resistance after coronary artery bypass surgery. Circulation 2003;108:542-547.
33. Halushka MK, Walker LP, Halushka PV: Genetic variation in cyclooxygenase 1: effects on response to aspirin. Clin Pharmacol Ther 2003;73:122-130.
34. Hillarp A, Palmqvist B, Lethagen S, Villoutreix BO, Mattiasson I: Mutations within the cyclooxygenase-1 gene in aspirin non-responders with recurrence of stroke. Thromb Res 2003;112:275-283.
35. Kawasaki T, Ozeki Y, Igawa T, Kambayashi J: Increased platelet sensitivity to collagen in individuals resistant to low-dose aspirin. Stroke 2000;31:591-595.
36. Nieswandt B, Watson SP: Platelet-collagen interaction: is GPVI the central receptor? Blood 2003;102:449-461.
37. Calverley DC, Brass E, Hacker MR, Tsao-Wei DD, Espina BM, Pullarkat VA, Hodis HN, Groshen S: Potential role of platelet Fc-γRIIA in collagen-mediated platelet activation associated with atherothrombosis. Atherosclerosis 2002;164:261-267.
38. 1 might be a genetic risk factor for the development of stroke in younger patients. Blood 1999;93:3583-3586.
39. Watson S, Berlanga O, Best D, Frampton J: Update on collagen receptor interactions in platelets: is the two-state model still valid? Platelets 2000;11:252-258.